Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20769518 | 0.94 | BTK (0.36) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL20769504 | 0.94 | BTK (0.36) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL15191538 | 0.73 | BTK (0.44) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL12493050 | 0.73 | BTK (0.44) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL24821867 | 0.73 | BTK (0.44) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL27936020 | 0.73 | BTK (0.37) | BTKEPHX1GAACA2CA12 | |
| SCHEMBL22203922 | 0.71 | BTK (0.45) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL7926853 | 0.71 | BTK (0.45) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL23285227 | 0.71 | EPHX1 (0.42) | BTKEPHX1GAACA2KMT2A | |
| SCHEMBL13687833 | 0.71 | BTK (0.42) | BTKEPHX1GAACA2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3936190-A1 | PENTACYCLIC HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2022-01-12 | — | — | EP | disclosed |
| EP-3680243-B1 | PENTACYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2021-10-27 | — | — | EP | disclosed |
| CN-113453762-A | Pentacyclic heterocyclic compounds | 卫材R&D管理有限公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3680243-A1 | PENTACYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-10239889-B1 | Pentacyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239889-B1 | Pentacyclic compound | CYP2B6, CYP11B2, CYP3A5 | BTK 4324/4885EPHX1 1007/4885GAA 456/4885 |
| US-20190071452-A1 | PENTACYCLIC COMPOUND | CYP2B6, CYP3A5, CYP4A11 | BTK 4552/4885EPHX1 1234/4885GAA 808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.